Results 161 to 170 of about 5,794,747 (285)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Are health care payments in Albania catastrophic? Evidence form ALSMS 2002, 2005 and 2008 [PDF]

The absent or poorly functioning risk pooling mechanisms and high amounts of out-of-pocket payments for health care expose households to financial risks associated with major illnesses or accidents. The aim of this paper is to analyse the extent to which
Packard, Truman G., Tomini, Sonila
core  

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

High-value, data-informed, and team-based care for multimorbidity

The Lancet Public Health, 2020
Arnaud Chiolero, Nicolas Rodondi, Valérie Santschi   +2 more
doaj   +1 more source

Lifestyle Medicine: A Foundational Framework for High-Value Care. [PDF]

Am J Lifestyle Med
Patel P.
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Corrigendum to “Design and methods of an adaptive trial to test comparative effectiveness of readmission reduction approaches following infection and sepsis hospitalizations (ACCOMPLISH)” [Contemp. Clinic. Trials Commun. 46 (2025) 101504]

Contemporary Clinical Trials Communications
Kristin Mayes, Victor B. Talisa, Adelina Malito, Florian B. Mayr, Kelly Williams, Kalpana Char, Richard Wadas, Elizabeth Lorenzi, Kert Viele, Rana Awdish, Derek C. Angus, Chung-Chou Ho Chang, Sachin Yende   +12 more
doaj   +1 more source

Reducing Laboratory Testing and Blood Draws in the Newborn Nursery to Increase High-value Care. [PDF]

Pediatr Qual Saf
Foster LZ, Natale L, Lukaszewicz J, Kleynerman M, Colameco J, Weckesser J, Ortale C, Haines E.   +7 more
europepmc   +1 more source

The paediatrician as a leader: A resident educational intervention for high-value care. [PDF]

Paediatr Child Health, 2020
Foulds JL, Forbes KL.
europepmc   +1 more source

Patient-centered high-value integrated care

Asian Biomedicine, 2022
openaire   +2 more sources